Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum

European Journal of Biochemistry

Volumn 268, Issue 11, 2001, Pages 3304-3312

  Gopal, Venkatesh K ^a   Francis, Sharron H ^a   Corbin, Jackie D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic nucleotide dependent protein kinases; Penile erection; Sildenafil; Vascular smooth muscle

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP PHOSPHODIESTERASE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CORPUS CAVERNOSUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; MALE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE RELAXATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ALLOSTERIC SITE; ANIMALS; CARRIER PROTEINS; CHROMATOGRAPHY, DEAE-CELLULOSE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; FEEDBACK; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PENIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RABBITS; SIGNAL TRANSDUCTION; TISSUE EXTRACTS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0034838812     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2001.02233.x     Document Type: Article

References (38)

1. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum
2. Nitric oxide in the penis: Physiology and pathology
3. Update on male erectile dysfunction
4. Cyclic GMP phosphodiesterase 5: Target for sildenafil
5. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
6. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities
7. Evidence for separate sites of action for the antilipolytic effects of insulin and prostaglandin E1
8. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)
9. cAMP-dependent protein kinase activation lowers hepatocyte cAMP
10. The short-term activation of a Rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation
11. Characterization of a hormone-inducible, high affinity adenosine 3′-5′-cyclic monophosphate phosphodiesterase from the rat Sertoli cell
12. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP
13. Cyclic nucleotide-binding domains in proteins having diverse functions
14. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries
15. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase
16. Phosphodiesterases in visual transduction by rods and cones
17. Purification of type I alpha and type I beta isozymes and proteolyzed type I beta monomeric enzyme of cGMP-dependent protein kinase from bovine aorta
18. Phosphorylation by guanosine 3′:5′-monophosphate-dependent protein kinase of synthetic peptide analogs of a site phosphorylated in histone H2B
19. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase
20. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues
21. Characterization of a novel isozyme of cGMP-dependent protein kinase from bovine aorta
22. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase
23. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum
24. Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases
25. Properties of a cGMP-dependent monomeric protein kinase from bovine aorta
26. Purification and assay of cAMP, cGMP, and cyclic nucleotide analogs in cells treated with cyclic nucleotide analogs
27. The L-arginine-nitric oxide-cyclic GMP pathway mediates inhibitory nonadrenergic-noncholinergic neurotransmission in the corpus cavernosum of human and rabbit
28. Characterization of a novel cGMP binding protein from rat lung
29. Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric cyclic nucleotide-binding sites of the cGMP-binding cGMP-specific phosphodiesterase
30. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells
31. Involvement of cAMP-dependent protein kinase in the regulation of heart contractile force
32. Primary structure and functional expression of a cyclic nucleotide-gated channel from rabbit aorta
33. Primary structure and functional expression of a cGMP-gated potassium channel
34. Energetics of ligand binding to protein
35. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation
36. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
37. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro
38. Overall cardiovascular profile of sildenafil citrate